Vipalanebart Biosimilar - Research Grade

Human

ADCYAP1R1ï؟½

5mg/ml

IgG4 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P41586

Blue ice

The PAC1 receptor (ADCYAP1R1) binds PACAP and modulates neuronal signaling, vascular tone, and pain pathways of growing interest in neuroscience and migraine research. Offered as an unconjugated, non-therapeutic analog of vipalanebart, this IgG4 recombinant human antibody targets ADCYAP1R1 and is supplied for research use only (RUO). It is purified to a low-endotoxin level suitable for in vivo work and manufactured in scalable milligram-to-gram quantities for high-throughput and heavy-usage laboratories. Applications include receptor-blocking and binding assays, in vitro PACAP-signaling screens, control reagents, and preclinical models of neurogenic pathways.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks